|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Investment securities: | ||||||||||||||||||||
| Held to maturity debt securities (Market value of $4,400 on June 30, 2026 and $4,400 on December 31, 2025) | ||||||||||||||||||||
| Available for sale debt securities (Amortized cost of $5,439,382 on June 30, 2026 and $5,281,090 on December 31, 2025) | ||||||||||||||||||||
| Equity securities with readily determinable fair values | ||||||||||||||||||||
| Total investment securities | ||||||||||||||||||||
| Loans | ||||||||||||||||||||
| Less allowance for credit losses | ||||||||||||||||||||
| Net loans | ||||||||||||||||||||
| Bank premises and equipment, net | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Other investments | ||||||||||||||||||||
| Cash surrender value of life insurance policies | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Shareholders' Equity | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Deposits: | ||||||||||||||||||||
| Demand-non-interest bearing | ||||||||||||||||||||
| Savings and interest bearing demand | ||||||||||||||||||||
| Time | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Securities sold under repurchase agreements | ||||||||||||||||||||
| Other borrowed funds | ||||||||||||||||||||
| Junior subordinated deferrable interest debentures | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders' equity: | ||||||||||||||||||||
| Common shares of $1.00 par value. Authorized 275,000,000 shares; issued 96,680,381 shares on June 30, 2026 and 96,658,794 shares on December 31, 2025 | ||||||||||||||||||||
| Surplus | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total shareholders' equity before treasury stock | ||||||||||||||||||||
| Less cost of shares in treasury, 34,492,192 shares on June 30, 2026 and 34,490,048 on December 31, 2025 | ||||||||||||||||||||
| Total shareholders' equity | ||||||||||||||||||||
| Total liabilities and shareholders' equity | ||||||||||||||||||||
Loading...
